What Has Been Advanced Liver Cancer Market in Recent Years?
The advanced liver cancer market has seen considerable growth due to a variety of factors.
• The market size for advanced liver cancer has seen a swift expansion in recent years. It is projected to rise from $1.89 billion in 2024 to $2.17 billion in 2025, equating to a compound annual growth rate (CAGR) of 15.2%.
Factors contributing to this significant growth during the historic period include higher awareness about liver cancer, an increase in the number of patients, a surge in demand for targeted therapies, growth in healthcare infrastructure, and an escalating demand for minimally invasive treatments.
What Is the Forecasted Market Size and Growth Rate for The Advanced Liver Cancer Market?
The advanced liver cancer market is expected to maintain its strong growth trajectory in upcoming years.
• The market for advanced liver cancer is projected to experience accelerated growth in the coming years, escalating to a value of $3.78 billion in 2029, with a compound annual growth rate of 14.8%.
This anticipated growth during the forecast period is likely due to the rising incidences of liver cancer, stepped-up healthcare expenditure, growing frequency of genetic conditions, enhanced adoption of precision medicine, and the utilization of screening and diagnostic tests. Significant trends for the projected period encompass the incorporation of artificial intelligence in treatments, the creation of groundbreaking drugs and treatments, an increase in research and development activities, advancements in targeted therapeutics, and the escalating demand for personalized medicine.
What Factors Are Driving Growth In The Advanced Liver Cancer Market?
The escalation in long-term hepatitis infections is predicted to fuel the growth of the advanced liver cancer market in the future. Persisting viral infections that last over six months, known as long-term hepatitis infections, could lead to liver damage, cirrhosis, or even liver cancer. Several factors, including insufficient screening and vaccination and delayed access to medical care, are behind the uptick in these infections. Chronic hepatitis B (HBV) or hepatitis C (HCV) infections are prominent causes of liver cirrhosis and hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. These enduring viral conditions can result in liver inflammation, damage, and ultimately cancer over time. As the prevalence of these infections continues, a greater number of individuals are at risk for advanced liver cancer. To exemplify, in April 2024, the World Health Organization, based in Switzerland, stated that chronic hepatitis B affected 254 million people globally in 2022, and 1.2 million new cases were reported each year. Therefore, the increasing occurrence of long-term hepatitis infections is bolstering the growth of the advanced liver cancer market.
What Are The Main Segments Of The Global Advanced Liver Cancer Market?
The advanced liver cancer market covered in this report is segmented –
1) By Test Type: Imaging Test, Biopsy, Genomic Test, Other Test Types
2) By Technology: Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluoroimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, Other Technologies
3) By Distribution Channel: Direct Tenders, Retail Sales, Other Distribution Channel
4) By Application: Screening, Diagnostic And Predictive, Prognostic, Research
5) By End-User: Hospitals, Cancer Research Centers, Academic Institutes, Diagnostic Centers, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Imaging Test: Ultrasound, CT (Computed Tomography) Scan, MRI (Magnetic Resonance Imaging), PET (Positron Emission Tomography) Scan
2) By Biopsy: Needle Biopsy, Laparoscopic Biopsy, Surgical Biopsy
3) By Genomic Test: Next-Generation Sequencing (NGS), PCR (Polymerase Chain Reaction) Testing, Genetic Mutation Profiling
4) By Other Test Types: Serum Biomarker Testing, Liver Function Tests, Alpha-Fetoprotein (AFP) Test, Elastography Tests
Pre-Book The Advanced Liver Cancer Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Advanced Liver Cancer Market?
Prominent players in the advanced liver cancer market are concentrating on the creation of novel drugs, such as human monoclonal antibodies, to enhance treatment effectiveness and lessen side effects, leading to improved patient results. Human monoclonal antibodies are laboratory-made molecules designed to mimic the immune system's role in battling harmful pathogens or cancer cells. They specifically target antigens on the surfaces of these detrimental entities, prompting an immune reaction. As an example, AstraZeneca, a pharmaceutical firm based in the US, announced in October 2022 that the US Food and Drug Administration (FDA) has endorsed Imjudo (tremelimumab) and Imfinzi (durvalumab) for usage in treating adult patients with inoperable hepatocellular carcinoma (HCC), the dominant type of liver cancer. The FDA approval was grounded on findings from the HIMALAYA Phase III trial, indicating that this combined therapy lessened death risk by 22% compared to sorafenib, with roughly 31% of patients surviving after three years compared to 20% for sorafenib patients. This method, identified as STRIDE, includes an initial dosage of Imjudo succeeded by regular four-week intervals of Imfinzi, thereby providing a fresh treatment alternative for patients with few existing options.
Who Are the Key Players in the Advanced Liver Cancer Market?
Major companies operating in the advanced liver cancer market are include:
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Merck Co. Inc.
• Bayer AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Novartis AG
• Eli Lilly and Company
• Stryker Corporation
• Agilent Technologies Inc.
• Eisai Co. Ltd.
• Jiangsu Hengrui Pharmaceutical Co. Ltd
• Exelixis Inc.
• Sirtex Medical Limited
• Eureka Therapeutics
• Abbisko Therapeutics Co. Ltd.
• Binhui Biopharmaceutical Co. Ltd.
• Tempest Therapeutics Inc.
• Auransa Inc.
• Mina Alpha Limited
• Jennerex Inc.
What Is The Most Dominant Region In The Advanced Liver Cancer Market?
North America was the largest region in the advanced liver cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced liver cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
